Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Feb 05, 2024 11:51am
435 Views
Post# 35863154

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studied

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studied

I don't mind repeating the answers to reasonable questions.
regarding Onc doing a phase 3 on their own?
It always ( since incorporation & original mission statement), to get Pela to a stage of approval, then partner &/ or be sold.
Partnering has always been their public discussion. Up to & including present day on- line corporate update.
ONC has $$$ funding to operate 12+ months. Ridding Andrew G wages & sanDiego office certainly will help marginally with operational costs.
They do not have $$$ to fund a phase 3 trial, 
meaning
1. accelerated approval
2. a pharma license parter deal
3. complete buyout
4. A significant share/ warrent bought deal
5. some other business arrangement, providing funding.

The PanCan arrangement was to solve most of the phase 3 trial timing & costs, but not all. 

going by Onc publicized updates etc:

We know phase 3 for panc will happen. It looks to be co- Theapy with Roche.
beyond that?
Stay tuned.
 

<< Previous
Bullboard Posts
Next >>